Drugs like Ozempic may lower cancer risk if you have diabetes: study
Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.
This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.
'This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,' said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.
The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University's Grossman School of Medicine.
Story continues below advertisement
1:54
GLP-1 drugs like Ozempic, Wegovy reduce Alzheimer's risk for those with diabetes
'Chronic disease and chronic disease prevention are some of my passions,' said Mavromatis, a former research fellow with an NIH training program.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.
In the study, researchers analyzed data from 43 U.S. health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.
After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.
Story continues below advertisement
The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
a day ago
- CTV News
Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch
The weight-loss drug Wegovy is shown in this undated photo. THE CANADIAN PRESS/handout, Novo Nordisk Canada Inc. Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy. The fall comes after U.S. President Donald Trump on Thursday sent letters to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. That prompted share price declines across the sector. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23 per cent on the day. Novo became Europe's most valuable listed company following the launch of Wegovy in June 2021. But its shares have plunged by more than two-thirds since peaking last year on concerns the drugmaker is losing ground in the obesity drug race. 'The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices,' Novo said in an emailed statement. Novo's shares were 4.9 per cent lower at 08:39 GMT. Friday's drop brings this week's losses to more than 30 per cent - the stock's worst-ever weekly fall. The European healthcare index .SXDP was down 1.6 per cent, its lowest since April. 'Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade,' said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly LLY.N and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. 'This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump,' Hansen said. (Reporting by Anna Pruchnicka, Elviira Luoma, Jacob Gronholt-Pedersen and Louise Breusch Rasmussen. Editing by Amanda Cooper and Mark Potter)
The Province
a day ago
- The Province
Three factors will stall dementia and the aging process, according to new U.S. study
The senior director of research strategy at Banner Alzheimer's Institute presented the findings at an annual conference of experts in Toronto Illustration of dementia as memory loss due to brain degeneration and decline. Photo by wildpixel / Getty Images By 2050, over 1.7 million Canadians are projected to be living with dementia. This represents an increase of 187 per cent compared to 2020, when approximately 597,300 Canadians were living with dementia, according to the Alzheimer's Society of Canada. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Dementia describes the decline of mental ability, while Alzheimer's Disease is the medical term for the brain disease that commonly causes dementia. Researchers are now saying certain lifestyle changes can stave off mental decline. A new U.S. study sets out what Alzheimer's researchers are calling the strongest evidence yet regarding what is involved in slowing the aging process and improving cognition. It comes down to three key factors: a diet heavy on leafy greens, berries and grains, regular moderate exercise and ongoing social interaction. Regular cardiovascular monitoring is also a factor. Jessica Langbaum, senior director of research strategy at the Banner Alzheimer's Institute in Phoenix was not involved directly in the research but she presented the findings at an annual conference of experts in Toronto on Wednesday. Essential reading for hockey fans who eat, sleep, Canucks, repeat. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. The Alzheimer's Association International Conference (AAIC) is the largest international meeting dedicated to advancing dementia science and clinical practice. This year's gathering brought together 8,000 scientists and clinicians from all over the world, with the goal of improving diagnosis, risk reduction and treatment. The study pulled together diet, exercise and socialization in one substantial, structured study of 2,100 people in their 60s and 70s at risk of developing dementia, showing that bad habits 'can really slow down memory and thinking' in adults at risk for cognitive impairment and dementia, Langbaum told the PBS New Hour in an interview on Wednesday evening. The subjects who participated in the study changed their habits, shifting from a sedentary lifestyle to an active one and improving their diet over a two-year period, resulting in cognitive function scores on par with people one or two years younger. This advertisement has not loaded yet, but your article continues below. That might not sound like much, but Langbaum says the results are significant evidence that change can occur without medication. 'And so, it's showing that we can change the trajectory of aging,' she said. There were two groups in the study. In one, lifestyle changes were structurally prescribed. In the other, the changes were self-directed. The results for the prescribed group were much better, but Langbaum says both groups showed improvement. The biggest challenge that study participants faced was sustaining a new exercise regime. Langbaum recommends people find something that they enjoy doing. 'If (you're) frustrated by it, (you're) just going to give up. But do something that you enjoy. Better yet, do it with somebody else or others around you because socialization is key, and lastly, something that you can adhere to, if you can schedule it. It's something that you can stay committed to.' This advertisement has not loaded yet, but your article continues below. Regarding nutrition she notes: 'We say what's good for the heart is good for the brain, so a nice balanced … nutritious diet with … those leafy greens, low in saturated fats, all of those things.' The American Alzheimer's Association spent close to US$50 million on the study. The National Institutes of Health spent even more to ensure many of the participants underwent brain scans, blood tests and sleep studies aimed at provide additional information down the road. Meanwhile, Langbaum expresses concern that structured intervention may not be sustainable in most communities. 'I think that's really the next stage of the research is, how do we make this scalable in communities so that people can implement these things into their daily lives?' This advertisement has not loaded yet, but your article continues below. The American Alzheimer's Association is planning to spend another US$40 million on implementing the lessons of the study. Langbaum says that will come with a change in the mindsets of doctors. They 'should be treating lifestyle interventions as they would a drug,' she told NPR. That would mean prescribing improved exercise and eating regimens and getting insurers to cover those prescriptions, she added. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here. Vancouver Whitecaps Vancouver Canucks Sports Vancouver Whitecaps Celebrity
Calgary Herald
2 days ago
- Calgary Herald
Three factors will stall dementia and the aging process, according to new U.S. study
By 2050, over 1.7 million Canadians are projected to be living with dementia. This represents an increase of 187 per cent compared to 2020, when approximately 597,300 Canadians were living with dementia, according to the Alzheimer's Society of Canada. Article content Dementia describes the decline of mental ability, while Alzheimer's Disease is the medical term for the brain disease that commonly causes dementia. Article content Article content Article content Researchers are now saying certain lifestyle changes can stave off mental decline. A new U.S. study sets out what Alzheimer's researchers are calling the strongest evidence yet regarding what is involved in slowing the aging process and improving cognition. Article content Article content It comes down to three key factors: a diet heavy on leafy greens, berries and grains, regular moderate exercise and ongoing social interaction. Regular cardiovascular monitoring is also a factor. Article content Jessica Langbaum, senior director of research strategy at the Banner Alzheimer's Institute in Phoenix was not involved directly in the research but she presented the findings at an annual conference of experts in Toronto on Wednesday. The Alzheimer's Association International Conference (AAIC) is the largest international meeting dedicated to advancing dementia science and clinical practice. This year's gathering brought together 8,000 scientists and clinicians from all over the world, with the goal of improving diagnosis, risk reduction and treatment. Article content Article content The study pulled together diet, exercise and socialization in one substantial, structured study of 2,100 people in their 60s and 70s at risk of developing dementia, showing that bad habits 'can really slow down memory and thinking' in adults at risk for cognitive impairment and dementia, Langbaum told the PBS New Hour in an interview on Wednesday evening. Article content The subjects who participated in the study changed their habits, shifting from a sedentary lifestyle to an active one and improving their diet over a two-year period, resulting in cognitive function scores on par with people one or two years younger. Article content That might not sound like much, but Langbaum says the results are significant evidence that change can occur without medication. 'And so, it's showing that we can change the trajectory of aging,' she said. Article content There were two groups in the study. In one, lifestyle changes were structurally prescribed. In the other, the changes were self-directed. The results for the prescribed group were much better, but Langbaum says both groups showed improvement.
